ASCO 2017

Wait Times From Cancer Diagnosis to First Treatment Longer, Negative Impact on Survival

Wait Times From Cancer Diagnosis to First Treatment Longer, Negative Impact on Survival

By

Data from the National Cancer Database are indicating that wait times from cancer diagnosis to initial treatment were substantially longer over a 5-year period.

Adding Pertuzumab to Adjuvant Therapy Is Beneficial for Some Women with Early Breast Cancer

Adding Pertuzumab to Adjuvant Therapy Is Beneficial for Some Women with Early Breast Cancer

By

Adding a second HER2-blocker to standard care therapy after surgery for HER2-positive breast cancer may be modestly beneficial for some women.

Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC

Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC

By

Phase 3 clinical trial results show fewer adverse effects and longer survival with alectinib compared with crizotinib in patients with treatment-naïve ALK-positive NSCLC.

Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men

Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men

By

A survey of men with prostate cancer revealed that treatment-related factors impact treatment decisions differently in black men compared with white men.

ASCO: CAR T-Cell Therapy Promising for Multiple Myeloma

ASCO: CAR T-Cell Therapy Promising for Multiple Myeloma

Findings from trial of chimeric antigen receptor T cells targeting B-cell maturation protein demonstrated promising results.

Older Patients Under-Represented in Cancer Drug Clinical Trials

Older Patients Under-Represented in Cancer Drug Clinical Trials

Older adults are underrepresented in clinical trials of cancer drugs, according to study findings presented at the 2017 ASCO Annual Meeting.

Self-Reports on Adverse Effects From Younger Patients Are Reliable, Accurate

Self-Reports on Adverse Effects From Younger Patients Are Reliable, Accurate

By

Children and adolescent patients with cancer are able to accurately report subjective adverse events (AEs) they experience during their cancer treatment, and they are willing to do so.

Checkpoint Inhibitors Appear Safe for Pediatric Cancer Patients

Checkpoint Inhibitors Appear Safe for Pediatric Cancer Patients

By

The medications so far show little efficacy in children with cancer, but new studies may provide clues to how to change this, pediatric oncologist says.

Pembrolizumab Use With CRT Safe in Locally Advanced HNSCC

Pembrolizumab Use With CRT Safe in Locally Advanced HNSCC

By

Small study also showed that pembrolizumab does not significant impair radiation or chemotherapy dosing.

Ovarian Function Recovery May Increase Risk of Breast Cancer Recurrence

Ovarian Function Recovery May Increase Risk of Breast Cancer Recurrence

By

Ovarian function recovery (OFR) in women with chemotherapy-induced ovarian function failure decreases residual 5-year disease-free and overall survival.

Adjuvant + Neoadjuvant Pembrolizumab Safe in Patients Undergoing HNSCC Surgery

Adjuvant + Neoadjuvant Pembrolizumab Safe in Patients Undergoing HNSCC Surgery

By

Study also provides evidence supporting an anti-tumor effect associated with a single preoperative dose of pembrolizumab.

Older Adults Under-Represented in Cancer Drug Clinical Trials

Older Adults Under-Represented in Cancer Drug Clinical Trials

By

Patients aged 80 years and older had a cancer incidence of 16% in 2013 yet made up only 4% of cancer drug clinical trial participants during 2005-2015.

Better Understanding of Prostate Cancer Genetic Test Results Needed

Better Understanding of Prostate Cancer Genetic Test Results Needed

By

Some men who undergo multigene testing for inherited prostate cancer misinterpret findings of variants of uncertain significance.

Neurocognitive Function Impacts Health-Related QOL in Advanced Lung Cancer

Neurocognitive Function Impacts Health-Related QOL in Advanced Lung Cancer

By

Study finds a correlation between various measures of neurocognitive function and health utility scores.

Adherence to Geriatric Assessment-Based Recommendations Probed

Adherence to Geriatric Assessment-Based Recommendations Probed

By

Older patients with cancer most frequently adhere to recommendations to see a dietitian for nutritional issues.

Symptom Burden Predictive of Hospital Discharge Location

Symptom Burden Predictive of Hospital Discharge Location

By

Greater symptom burden in hospitalized advanced cancer patients ups the likelihood of being discharged to a post-acute care facility or hospice.

Novel Approach Increases Breast, Ovarian Cancer Genetic Screening

Novel Approach Increases Breast, Ovarian Cancer Genetic Screening

By

A questionnaire added to intake forms at a breast cancer imaging center identified women with BRCA mutations who might otherwise have been missed.

Interactive Tool Improves Breast Cancer Treatment Decision-Making

Interactive Tool Improves Breast Cancer Treatment Decision-Making

By

A tool called iCanDecide prepares patients for making decision about treatment better than static online information, study finds.

Patient Navigators Found to Boost Lung Cancer Screening Rates

Patient Navigators Found to Boost Lung Cancer Screening Rates

By

Counseling current smokers and helping to direct their care may reduce lung cancer mortality in underserved low-income populations.

Cognitive Computing Expedites Matching Patients to Clinical Trials

Cognitive Computing Expedites Matching Patients to Clinical Trials

By

IBM Watson for Clinical Trial Matching compares study enrollment criteria with patient data in electronic medical records.

Survival Increased With First-Line Abiraterone-ADT Combination for Hormone-Naïve Prostate Cancer

Survival Increased With First-Line Abiraterone-ADT Combination for Hormone-Naïve Prostate Cancer

By

Addition of abiraterone to androgen deprivation therapy for patients with hormone-naïve advanced prostate cancer may be a new standard of care.

Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma

Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma

By

Five-year survival rate found similar to observation despite a significant improvement in disease-free interval.

Pediatric Acute Lymphoblastic Leukemia Extramedullary Relapse Responds to CAR-T

Pediatric Acute Lymphoblastic Leukemia Extramedullary Relapse Responds to CAR-T

By

Children with extramedullary relapse of CD19+ acute lymphoblastic leukemia experienced a potent and durable response to the immunotherapy.

Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival

Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival

By

Study of patients with resected high-risk melanoma reveals higher rates of treatment-related adverse events with 10 vs 3 mg/kg.

Treatment for Breast Cancer in Men Differs From Treatment for Women

Treatment for Breast Cancer in Men Differs From Treatment for Women

By

Male breast cancer patients are less likely than their female counterparts to receive adjuvant hormone therapy and postlumpectomy radiation.

Unexplained Leukocytosis, Thrombocytosis in MPN Warrants Evaluation for CML

Unexplained Leukocytosis, Thrombocytosis in MPN Warrants Evaluation for CML

By

A chart review reveals 3 cases of CML developing in patients with diagnoses of ET and PV.

No Serious HRQOL Decline With FOLFOXIRI/Bevacizumab

No Serious HRQOL Decline With FOLFOXIRI/Bevacizumab

By

Study compared FOLFOXIRI/bevacizumab and FOLFOX/bevacizumab in patients with metastatic colorectal cancer.

Efficacy of Trastuzumab Biosimilars Shown Equivalent to Originator in HER2 Breast Cancer

Efficacy of Trastuzumab Biosimilars Shown Equivalent to Originator in HER2 Breast Cancer

By

Biosimilars and originator trastuzumab neoadjuvant therapy had a comparable effect on pathologic complete response rates.

Autologous T-Cell Therapy Promising in Advanced Sarcoma

Autologous T-Cell Therapy Promising in Advanced Sarcoma

By

After lymphodepletion in patients with advanced HER2+ sarcoma, T cells expanded in 5 of 6 patients who received infusions of HER2-CAR T cells.

CVD Risk Factors Identified in Long-Term Survivors of Pediatric Cancer

CVD Risk Factors Identified in Long-Term Survivors of Pediatric Cancer

By

Study implicates higher doses of cardiac radiotherapy and exposure to high-dose anthracyclines.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs